Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.71 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.71 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MIF | P14174 | 3/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11421518 | 0.87 | GABRA1 (0.67) | GABRA1GABRB2LMNAMIFTSHR | |
| SCHEMBL959941 | 0.86 | GABRA1 (0.52) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL1456958 | 0.85 | GABRA1 (0.70) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL1457256 | 0.84 | GABRA1 (1.00) | GABRA1GABRB2LMNAMIFCYP1A2 | |
| SCHEMBL1457748 | 0.84 | GABRA1 (0.48) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL27734967 | 0.83 | GABRA1 (0.49) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL11416607 | 0.81 | GABRA1 (0.55) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL11417964 | 0.80 | GABRA1 (0.47) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL8763645 | 0.79 | GABRA1 (0.89) | GABRA1GABRB2LMNAMIFCYP1A2 | |
| SCHEMBL332763 | 0.77 | GABRA1 (0.79) | GABRA1GABRB2LMNAMIFCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888596-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8772307-B2 | Substituted spiro compounds and their use for producing pain-relief medicaments | GRUENENTHAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-2292625-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-12-25 | — | — | EP | disclosed |
| EP-2292625-A1 | Substituted spiro compounds and their use for producing pain-relief medicaments | Grünenthal GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1893620-A2 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF DRUGS | Grünenthal GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1888596-A1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122769-A2 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006122770-A1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
| CN-1217715-A | 2-thioxotetrahydropyrimidin-4-one derivative | AMERICAN HOMA PRODUCTS CO (US) | 1999-05-26 | — | — | CN | disclosed |
| US-5861517-A | INCREASING BLOOD SERUM HIGH DENSITY LIPOPROTEINS LEVELS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| EP-0885197-A1 | 2-THIOXOTETRAHYDROPYRIMIDIN-4-ONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5807864-A | INCREASING HIGH DENSITY LIPOPROTEIN LEVELS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1997032855-A1 | 2-THIOXOTETRAHYDROPYRIMIDIN-4-ONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-09-12 | — | — | WO | disclosed |
| US-5554607-A | INCREASING HDL CHOLESTEROL | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-10 | — | — | US | disclosed |
| US-4194008-A | INSECTICIDE, FUNGICIDE, MITICIDE, PARASITICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-03-18 | — | — | US | disclosed |
| EP-0000365-A1 | N-aryl-N'-alcoyl-S-alcoyl isothioureas, process for their preparation and their use against animal and vegetal pests | BAYER AG (DE) | 1979-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | GABRA1 2625/4885GABRB2 3479/4885GABRG2 4067/4885 |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | INA, SCN1A, SI | GABRA1 492/4885GABRB2 474/4885GABRG2 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.